Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
West Virginia’s lawsuit against Janssen and others arrives amid a rise in HIV, hepatitis and overdose rates linked to the opioid crisis.
A slow vaccine rollout and the emergence of new coronavirus mutations threaten progress in reducing new cases and death.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
The Phase IIb trial investigated the safety and efficacy of the JNJ-4178 regimen, which includes odalasvir, AL-335 and Olysio.
The Johnson & Johnson research unit says the decision is strategic, citing a crowded HCV treatment market.
The triple-drug regimen comes in a once-daily single tablet.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.
What new therapies are being developed by the major players in hepatitis C pharmaceuticals?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.